Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765076 · ClinicalTrials.gov registry record · Phase 3
Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
NCT00765076 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 192 participants.
The verdict
NCT00765076, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
Study Summary
This clinical trial aims to study the immunogenicity of GSK Biologicals' influenza vaccine GSK2186877A in people aged 65 years or older.
Interventions
- BIOLOGICAL GSK Biologicals' influenza vaccine GSK2186877A
- BIOLOGICAL GSK Biologicals' Fluarix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2008-10-16 |
| Est. Completion | 2009-12-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00765076
The ClinicalTrials.gov registry entry for NCT00765076 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GSK Biologicals' influenza vaccine GSK2186877A is the first listed.
NCT00765076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00765076 about?
NCT00765076 is a clinical study titled "Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older". This clinical trial aims to study the immunogenicity of GSK Biologicals' influenza vaccine GSK2186877A in people aged 65 years or older.
What is the current status of trial NCT00765076?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2008-10-16. Estimated completion is 2009-12-04.
What interventions are being tested in trial NCT00765076?
The interventions under investigation include: GSK Biologicals' influenza vaccine GSK2186877A (BIOLOGICAL), GSK Biologicals' Fluarix (BIOLOGICAL).
Who is sponsoring clinical trial NCT00765076?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.